Q-omics provides the consensus-scored RPL9P31 profile across patient tissues and cancer cell-line models. RPL9P31 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RPL9P31 is differentially expressed in 3, with the highest sampling consensus in READ. Additionally, RPL9P31 RNA expression shows 6,129 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight OV, READ, and STAD as cancer lineages where RPL9P31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL9P31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL9P31 survival associations across molecular data types. RPL9P31 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL9P31 RNA expression–survival associations across cancer types. High RPL9P31 expression shows unfavorable associations in OV, KICH and LUAD, but favorable associations in READ, LAML and LGG. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify OV as the clearest survival context for RPL9P31 RNA expression.
This table summarizes RPL9P31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for RPL9P31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL9P31 shows lower tumor expression in READ and HNSC and higher tumor expression in LIHC. The READ box plot shows higher RPL9P31 RNA expression in normal versus tumor tissue (log2 FC = −0.145, t-test p = .028).
This table shows molecular features associated with RPL9P31 in patient tissues and cancer cell lines. In patient samples, RPL9P31 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
